Reference-Based Pricing — A “Transparent” Way of Paying Health Care Providers

By Manoj Rajwani, USI Vice President, Employee Benefits Employers and their employees continue to struggle with skyrocketing health care costs.  The job market is already competitive, and many companies are overwhelmed with  how to manage the benefit costs but still offer a quality program at the same time.  Many of those same organizations are diligent…

USI’s Manoj Rajwani to Present at ISCEBS Conference in NYC May 16

With health care costs on the rise and ongoing confusion around how claim costs are determined, it’s hard to advocate for your employees and save your organization valuable dollars on the benefit spend. Reference-based reimbursements (RBR’s) are just one way of tackling the exorbitant increases demanded by hospitals and providers. Hear from USI Vice President…

April 11: USI’s Mary Jo Jacobs to Speak at Panel Event on Rising Healthcare Costs

Healthcare is complicated! Hear from Mary Jo Jacobs of USI Insurance Services as she joins an esteemed panel of experts in a panel conversation to discuss the challenges of providing healthcare coverage and keeping costs down in today’s environment. The Westchester County Association (WCA) is hosting this educational networking event, which will be moderated by David…

How to Control Rising Drug Costs

Spending on prescription drugs in the United States accounted for nearly 17 percent of total health care spending — with a price tag of $457 billion in 2015. And that’s only going up, unless serious change occurs. The rapidly rising prices of prescription drugs, combined with increasingly higher cost-sharing, has shifted much of the costs…

Cancer Care and Your Employee Health Costs

The average cost of a course of branded cancer drugs has doubled over the past decade, reaching $10,000. That’s per month, not year. The cost of cancer drugs has gotten so high that even physicians are starting to notice. The American Society of Clinical Oncology discussed the cost versus benefit of various cancer drugs at…